

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-59 (canceled)

¹
Claim ~~60~~ (currently amended): A method for inhibiting $\alpha_v\beta_3$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_3$ antagonist, wherein said antagonist is a matrix metalloproteinase polypeptide consisting of: ~~that includes an amino acid sequence shown in~~ SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

Claims 61-64 (canceled)

²
Claim ~~65~~ (previously presented): The method of claim ~~60~~¹ wherein said tissue is human tissue.

³
Claim ~~66~~ (previously presented): The method of claim ~~65~~² wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

⁴
Claim ~~67~~ (previously presented): The method of claim ~~66~~³ wherein said tissue is arthritic.

⁵
Claim ~~68~~ (previously presented): The method of claim ~~67~~⁴ wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim ⁶~~6~~ (previously presented): The method of claim ¹~~6~~ wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim ⁷~~7~~ (previously presented): The method of claim ⁶~~6~~ wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim ⁸~~7~~ (previously presented): The method of claim ¹~~6~~ wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim ⁹~~7~~ (previously presented): The method of claim ⁸~~7~~ wherein said tissue is a carcinoma.

Claim ¹⁰~~7~~ (previously presented): The method of claim ⁸~~7~~ wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim ¹¹~~7~~ (previously presented): The method of claim ⁸~~7~~ wherein said administering is conducted in conjunction with chemotherapy.

Claim ¹²~~7~~ (previously presented): The method of claim ¹~~6~~ wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim ¹³~~7~~ (previously presented): The method of claim ¹~~6~~ wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim ¹⁴~~7~~ (previously presented): The method of claim ¹~~6~~ wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

¹⁵
Claim ~~78~~ (previously presented): The method of claim ~~60~~¹ wherein said administering comprises a single dose intravenously.

¹⁶
Claim ~~79~~ (previously presented): The method of claim ~~60~~¹ wherein said administering comprises one or more dose administrations daily for one or more days.

¹⁷
Claim ~~80~~ (previously presented): The method of claim ~~60~~¹ wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

¹⁸
Claim ~~81~~ (previously presented): The method of claim ~~60~~¹ wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.




¹⁹
Claim ~~82~~ (previously presented): The method of claim ~~60~~¹ wherein said angiogenesis is induced by a cytokine.



²⁰
Claim ~~83~~ (previously presented): The method of claim ~~82~~¹⁹ wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- α and epidermal growth factor.

²¹
Claim ~~84~~ (previously presented): The method of claim ~~82~~¹⁹ wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.

Claims 85-87 (canceled)

²²
Claim ~~88~~ (currently amended): A method for inhibiting $\alpha_v\beta_5$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_5$ antagonist, wherein said antagonist is an organic compound selected from the group consisting of compounds ~~7, 9, 10, 12, AND 14.~~ represented by the following structures:





²³
Claim ~~89~~ (previously presented): The method of claim ²²~~88~~ wherein said tissue is human tissue.

²⁴
Claim ~~90~~ (previously presented): The method of claim ²³~~89~~ wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

²⁵
Claim ~~91~~ (previously presented): The method of claim ²²~~88~~ wherein said tissue is arthritic.

²⁶
Claim ~~92~~ (previously presented): The method of claim ²⁵~~91~~ wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

²⁷
Claim ~~98~~ (previously presented): The method of claim ~~88~~²² wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

²⁸
Claim ~~94~~ (previously presented): The method of claim ~~93~~²⁷ wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

²⁹
Claim ~~95~~ (previously presented): The method of claim ~~88~~²² wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

³⁰
Claim ~~96~~ (previously presented): The method of claim ~~95~~²⁹ wherein said tissue is a carcinoma.

³¹
Claim ~~97~~ (previously presented): The method of claim ~~95~~²⁹ wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

³²
Claim ~~98~~ (previously presented): The method of claim ~~95~~²⁹ wherein said administering is conducted in conjunction with chemotherapy.

³³
Claim ~~99~~ (previously presented): The method of claim ~~88~~²² wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

³⁴
Claim ~~100~~ (previously presented): The method of claim ~~88~~²² wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

³⁵
Claim ~~101~~ (previously presented): The method of claim ~~88~~²² wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

³⁶
Claim ~~102~~ (previously presented): The method of claim ~~88~~²² wherein said administering comprises a single dose intravenously.

³⁷
Claim ~~103~~ (previously presented): The method of claim ~~88~~²² wherein said administering comprises one or more dose administrations daily for one or more days.

³⁸
Claim ~~104~~ (previously presented): The method of claim ~~88~~²² wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

³⁹
Claim ~~105~~ (previously presented): The method of claim ~~88~~²² wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

⁴⁰
Claim ~~106~~ (previously presented): The method of claim ~~88~~²² wherein said angiogenesis is induced by a cytokine.

⁴¹
Claim ~~107~~ (previously presented): The method of claim ~~106~~⁴⁰ wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- α and epidermal growth factor.

⁴²
Claim ~~108~~ (previously presented): The method of claim ~~106~~⁴⁰ wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.